A newly developed AR antagonist, proxalutamide, significantly inhibits proliferation and migration, induces the caspase-dependent apoptosis, and diminishes the level of lipid droplets in PCa cells by regulating the levels of ACL, ACC, FASN, and SREBP-1. Here, FASN is linked to posterior cortical atrophy.